tbuckley/cabot-search huggingface dataset:
Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis
Authors: Sonja Kroep, Curtis R. Heberle, Kit Curtius, Chung Yin Kong, Iris Lansdorp-Vogelaar, Ayman Ali, W. Asher Wolf, Nicholas J. Shaheen, Stuart J. Spechler, Joel H. Rubenstein, Norman S. Nishioka, Stephen J. Meltzer, William D. Hazelton, Marjolein van Ballegooijen, Angela C. Tramontano, G. Scott Gazelle, E. Georg Luebeck, John M. Inadomi, Chin Hur
Journal: Clinical Gastroenterology and Hepatology (2017)
Histone Deacetylase 11 (HDAC11) Regulates Cytotoxic T-Cell Function and Memory Phenotype
Authors: David M Woods, Karrune V. Woan, Eva Sahakian, John Powers, Fengdong Cheng, Hongwei Wang, Jennifer Rock-Klotz, Jeffrey S. Weber, Alejandro Villagra, Javier Pinilla-Ibarz, Eduardo M. Sotomayor
Journal: Blood (2012)
ACTR-44. TREATMENT OUTCOMES IN ELDERLY PATIENTS WITH GLIOBLASTOMA: THE CLEVELAND CLINIC EXPERIENCE
Authors: Suryanarayan Mohapatra, Erin Murphy, Samuel Chao, John Suh, Glen Stevens, David Peereboom, Jia Xuefei, Manmeet Ahluwalia
Journal: Neuro-Oncology (2016)

Fifty percent of glioblastoma patients are ≥ 65 years old. There is limited literature on outcomes of these patients. We report our experience with elderly patients with glioblastoma treated at our tertiary care center. With IRB approval, the Cleveland Clinic’s database was used to identify glioblastoma patients treated through 2000 - 2015. Overall survival (OS) from the diagnosis of glioblastoma was the primary end point. Cox proportional hazard models with stepwise variable selections were used for data analysis. 567 patients with a median age of 73 years (range, 65- 96 years), 57% of whom were male, were analyzed. Among 115 patients with known MGMT status, 54% were MGMT methylated. Twenty-eight percent of all patients underwent GTR (gross total resection), 28.8% had STR (sub-total resection) and 43.2% underwent biopsy. At diagnosis, 64% received chemoradiation, 34% underwent radiation and 2% received chemotherapy. The median OS and PFS (progression free survival) were 7.11 months (95% CI: 6.26, 8.65) and 4.0 months (CI: 3.6–4.5) respectively. The OS in MGMT-methylated patients was 12.85 months versus 8.46 months in MGMT-unmethylated ones (p 0.098). Patients with STR or biopsy had a higher risk of death and progression compared to GTR patients (p <0.001). The chemoradiation group had better PFS and OS compared to radiation alone; 6.197 versus 3.213 months (HR: 0.47, CI: 0.37 – 0.59, p <0.001) and 11.48 vs. 5.02 months (HR: 0.44, CI: 0.34 – 0.56, p <0.001) respectively. This effect was more evident in MGMT methylated patients; the chemoradiation group had a significantly higher OS than RT group 17.9 vs. 5.34 months (HR: 0.22, CI: 0.07 - 0.65, p 0.006) consistent with the recently reported Phase III study. Aggressive treatment with chemoradiation is associated with better outcomes in elderly GBM, particularly in MGMT methylated population.
Outcomes Analysis of Patients Surviving ≥2 Years after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).
Authors: Ronald Sobecks, Matt Kalaycio, Brad Pohlman, Steven Andresen, Lisa Rybicki, Jennifer Kosar, Mary Serafin, Karen Sands, Christy Lalli, Stacey Brown, Elizabeth Kuczkowski, Brian Bolwell
Journal: Blood (2004)
Comment on Pathak et al. Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005–2011. Diabetes Care 2016:39;363–370
Authors: Philip D. Home
Journal: Diabetes Care (2017)

Pathak et al. (1) record severe hypoglycemic events in “emergency department or inpatient medical encounters” and comment that they were “likely to have included some cases … that occurred as a consequence of treatment initiated after hospitalization.” The event rates they note are very high compared with reports from studies in ambulatory care. Is it not likely that the majority of events are indeed …
Monocyte-Derived Dendritic Cells Induce Functionally Active Regulatory T Cells Upon Exposure to BCR-ABL Tyrosine Kinase Inhibitors.
Authors: Michael Gutknecht, Simone Joas, Lisa Güttler, Lothar Kanz, Helmut R Salih, Frank Grünebach, Susanne M Rittig
Journal: Blood (2012)
NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment
Authors: Sabina Chiaretti, Marilisa Marinelli, Ilaria Del Giudice, Silvia Bonina, Sara Gabrielli, Alfonso Piciocchi, Monica Messina, Marco Vignetti, Davide Rossi, Valeria Di Maio, Francesca Romana Mauro, Anna Guarini, Gianluca Gaidano, Robin Foà
Journal: Blood (2012)
ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer
Authors: Tomasz B. Owczarek, Takashi Kobayashi, Ricardo Ramirez, Lijie Rong, Anna M. Puzio-Kuter, Gopa Iyer, Min Yuen Teo, Francisco Sánchez-Vega, Jingqiang Wang, Nikolaus Schultz, Tian Zheng, David B. Solit, Hikmat A. Al-Ahmadie, Cory Abate-Shen
Journal: Cancer Research (2017)

Muscle-invasive bladder cancer (MIBC) generally responds poorly to treatment and tends to exhibit significant mortality. Here we show that expression of the tumor suppressor p14
Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study
Authors: Joyce Habib, Neil Dunavin, Gary Phillips, Patrick Elder, Meaghan Tranovich, Don M Benson, Craig C. Hofmeister, John C. Byrd, Steven M. Devine, Yvonne Efebera
Journal: Blood (2010)
Preparation of Human Alloantigen-Specific Natural Regulatory T-Cells for the Control of Graft Versus Host Disease.
Authors: Yamina Hamel, Claude Baillou, Maude Guillot-Delost, Soumia Touil, Mustapha Cherai, Ghislaine Simonin, Sebastien Maury, David Klatzmann, José Cohen, Francois Michel Lemoine
Journal: Blood (2009)
Precision Phenotyping in Heart Failure and Pattern Clustering of Ultrasound Data for the Assessment of Diastolic Dysfunction
Authors: Alaa Mabrouk Salem Omar, Sukrit Narula, Mohamed Ahmed Abdel Rahman, Gianni Pedrizzetti, Hala Raslan, Osama Rifaie, Jagat Narula, Partho P. Sengupta
Journal: JACC. Cardiovascular imaging (2017)
Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients
Authors: Philip E. Silkoff, Michel Laviolette, Dave Singh, J. Mark FitzGerald, Steven Kelsen, Vibeke Backer, Celeste M. Porsbjerg, Pierre-Olivier Girodet, Patrick Berger, Joel N. Kline, Geoffrey Chupp, Vedrana S. Susulic, Elliot S. Barnathan, Frédéric Baribaud, Matthew J. Loza, I. Strambu, S. Lam, A. Eich, A. Ludwig-Sengpiel, R. Leigh, M. Dransfield, W. Calhoun, A. Hussaini, P. Chanez
Journal: Journal of Allergy and Clinical Immunology (2017)
PARENTHOOD IN SURVIVORS OF HODGKIN LYMPHOMA (HL): AN EORTC-GELA GENERAL POPULATION CASE-CONTROL STUDY
Authors: M. A. Van der Kaaij, N. Heutte, P. Meijnders, J. M. Raemaekers, A. Allgeier, A. H. Simons, N. Mounier, M. Henry-Amar, J. C. Kluin-Nelemans
Journal: Annals of Oncology (2011)
Single Versus Tandem High Dose Therapy (HDT) Supported with Autologous Blood Stem Cell (ABSC) Transplantation Using Unselected or CD34-Enriched ABSC: Long-Term Results of a Two by Two Designed Randomized Trial in 225 Young Patients with Multiple Myeloma (MM). for the Group “Myelome-Autogreffe”, Caen, Creteil, Limoges, Paris, Strasbourg, France.
Authors: Jean-Paul Fermand, Kristell Desseaux, Jean Pierre Marolleau
Journal: Blood (2009)
It is time to stop meniscectomy
Authors: Ewa M Roos, Jonas Bloch Thorlund
Journal: British Journal of Sports Medicine (2017)

Recently, the New York Times asked why ‘useless’ surgery is still popular.1 In this editorial we outline three factors that likely promote continuing use of arthroscopic partial meniscectomy, for more than 350 000 middle-aged and older Americans (>35 years) annually. These operations occur despite there being no scientific evidence for a benefit over placebo and despite clinical guidelines increasingly recommending against arthroscopic partial meniscectomy. We close with a call to action recommending patients, clinicians, researchers and funders to act and stop supporting ‘useless’ medical treatments.

A medical procedure is often accepted as effective if a logical story describes how symptoms arise and how the treatment provides a cure. The dogma that removing or trimming torn meniscal tissue is necessary to improve knee symptoms is outdated. Nine randomised studies provide strong evidence that knee arthroscopy provides no greater pain relief or other improvements when compared to placebo or added to exercise.2 Our recent randomised study compared exercise therapy of sufficient quality and …
Recognition of Megakaryocyte-Specific T-Antigen By Macrophages Negatively Regulates Platelet Production in Bone Marrow
Authors: Melissa M. Lee-Sundlov, Renata Grozovsky, Silvia Giannini, Martina McGrath, Haley Elizabeth Ramsey, Reza Abdi, Martha Sola-Visner, Karin M. Hoffmeister
Journal: Blood (2015)
Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study
Authors: Lia Bally, Hood Thabit, Harald Kojzar, Julia K Mader, Jehona Qerimi-Hyseni, Sara Hartnell, Martin Tauschmann, Janet M Allen, Malgorzata E Wilinska, Thomas R Pieber, Mark L Evans, Roman Hovorka
Journal: The Lancet Diabetes & Endocrinology (2017)

Tight control of blood glucose concentration in people with type 1 diabetes predisposes to hypoglycaemia. We aimed to investigate whether day-and-night hybrid closed-loop insulin delivery can improve glucose control while alleviating the risk of hypoglycaemia in adults with HbA
RPL27A Is a Target for Mir-595 and Contributes to Myelodysplastic Phenotype through Ribosomal Dysgenesis
Authors: Heba A Alkhatabi, Joop Gaken, Austin Kulasekararaj, Shengjiang Tan, Farooq Malik, Alan John Warren, Thomas Seidl, David C Darling, Ghulam Mufti
Journal: Blood (2014)
Oral Bioavailability of Mycophenolate Mofetil in Patients Undergoing Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Is Poor and Highly Variable.
Authors: Pamala Jacobson, Green Kathleen, John Rogosheske, Claudio Brunstein, Juliet Barker, Todd DeFor, Philip McGlave, Daniel Weisdorf
Journal: Blood (2005)
Inhibition of Phosphatidylinositol 3-Kinase Is Effective to Suppress the Growth of CD20-Negative Refractory Diffuse Large B-Cell Lymphoma Cells
Authors: Tsuyoshi Nakamaki, Kunihiko Fukuchi, Hidetoshi Nakashima, Hirotsugu Ariizumi, Takashi Maeda, Bungo Saito, Kouji Yanagisawa, Shigeru Tomoyasu, Eisuke Shiozawa, Toshiko Yamochi-Onizuka, Hidekazu Ota
Journal: Blood (2011)
Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.
Authors: Irene M. Ghobrial, Stacey Chuma, Amy Sam, Renee Leduc, Marybeth Nelson, Kelly O’Connor, Brianna Harris, Jacob Soumerai, Diane Warren, Eric Jacobsen, Daniel DeAngelo, Kenneth C. Anderson, Paul G. Richardson, Thomas E. Witzig, Steven P. Treon
Journal: Blood (2008)
Diffuse large B-cell lymphoma genotyping on the liquid biopsy
Authors: Davide Rossi, Fary Diop, Elisa Spaccarotella, Sara Monti, Manuela Zanni, Silvia Rasi, Clara Deambrogi, Valeria Spina, Alessio Bruscaggin, Chiara Favini, Roberto Serra, Antonio Ramponi, Renzo Boldorini, Robin Foà, Gianluca Gaidano
Journal: Blood (2017)
Preparing for the Next Terrorism Attack
Authors: Eric Goralnick, Frank Van Trimpont, Pierre Carli
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Surgeon faces trial for lying about his experience in keyhole technique
Authors: Clare Dyer
Journal: BMJ (2017)

A surgeon is to stand trial accused of lying about his experience in order to get a job as a consultant specialising in keyhole bowel surgery.

Sudip Sarker, 47, has been charged with fraud by misrepresentation after allegedly lying on his CV and at interview about the number of keyhole operations he had performed.

Sarker was ordered to appear …
Prospective evaluation of liposomal doxorubicin (LD) in patients (pts) with metastatic breast cancer (MBC) pretreated with conventional anthracyclines
Authors: D. Errante, D. Bernardi, M. Stefani, M. Ramello, A. Bianco, L. Salvagno
Journal: Journal of Clinical Oncology (2008)

12011 Background: The treatment of pts with MBC, who failed previous chemotherapy regimens and whose favourable performance status justifies further treatment, represents a significant challenge. In MBC the use of conventional anthracyclines is limited by cumulative cardiac toxicity and myelosuppression, despite long anthracycline-free intervals in many pts. In these cases LD may represent an attractive option. Methods: 15 pts with MBC already treated with different therapeutic strategies and previously exposed to conventional anthracyclines (epirubicin, EPI, in 9 pts and doxorubicin, DOX, in 6 pts), were treated with LD 60 mg/m2 every 3 weeks. Results: Median age was 54 years. Median time from conventional anthracycline exposure was 40 months. Median previous dose of EPI was 440 mg/m2 and of DOX was 240 mg/m2. All pts had a LVEF>50% at baseline. The median number of previous chemotherapy regimens was 4. The median number of cycles of LD administered was 4. G3-G4 hematologic occurred in 6 pts. A delay or reduction of chemotherapy was necessary in 3 pts. There were 3 pts with asymptomatic cardiologic events (>20% reduction in LVEF in 1 pt after 10 cycles, 10% reduction in LVEF in 2 pt after 5 and 6 cycles, respectively). These pts received a median previous dose of anthracyclines of 350 mg/m2 and were previously exposed to RT and trastuzumab (2 out of 3). A congestive heart failure was registered in 1 pt after 6 cycles, an adjuvant dose of doxorubicin of 240 mg/m2 and RT for metastatic disease. Partial response was achieved in 3 pts and stable disease in 1 (i.e. clinical benefit in 4 patients). Median duration of the clinical benefit was 6.5 months, median overall survival was 5 months. Conclusions: LD appears to be effective even in pts with MBC heavily pre-treated, with manageable hematologic toxicity. Nevertheless, cardiac function should be monitored carefully especially in pts treated for long periods of time. No conclusion on survival can be made. However, the median survival time of 5 months compares favourably with the median survival reported in the literature suggesting that LD monotherapy should be considered as a valuable treatment option in heavily pre-treated pts. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Cephalon
Potent and broad HIV-neutralizing antibodies in memory B cells and plasma
Authors: LaTonya D. Williams, Gilad Ofek, Sebastian Schätzle, Jonathan R. McDaniel, Xiaozhi Lu, Nathan I. Nicely, Liming Wu, Caleb S. Lougheed, Todd Bradley, Mark K. Louder, Krisha McKee, Robert T. Bailer, Sijy O’Dell, Ivelin S. Georgiev, Michael S. Seaman, Robert J. Parks, Dawn J. Marshall, Kara Anasti, Guang Yang, Xiaoyan Nie, Nancy L. Tumba, Kevin Wiehe, Kshitij Wagh, Bette Korber, Thomas B. Kepler, S. Munir Alam, Lynn Morris, Gift Kamanga, Myron S. Cohen, Mattia Bonsignori, Shi-Mao Xia, David C. Montefiori, Garnett Kelsoe, Feng Gao, John R. Mascola, M. Anthony Moody, Kevin O. Saunders, Hua-Xin Liao, Georgia D. Tomaras, George Georgiou, Barton F. Haynes
Journal: Science Immunology (2017)

Induction of broadly neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development. Antibody 10E8, reactive with the distal portion of the membrane-proximal external region (MPER) of HIV-1 gp41, is broadly neutralizing. However, the ontogeny of distal MPER antibodies and the relationship of memory B cell to plasma bnAbs are poorly understood. HIV-1-specific memory B cell flow sorting and proteomic identification of anti-MPER plasma antibodies from an HIV-1-infected individual were used to isolate broadly neutralizing distal MPER bnAbs of the same B cell clonal lineage. Structural analysis demonstrated that antibodies from memory B cells and plasma recognized the envelope gp41 bnAb epitope in a distinct orientation compared with other distal MPER bnAbs. The unmutated common ancestor of this distal MPER bnAb was autoreactive, suggesting lineage immune tolerance control. Construction of chimeric antibodies of memory B cell and plasma antibodies yielded a bnAb that potently neutralized most HIV-1 strains.
2-Oxoglutarate Down-Regulates Expression of Vascular Endothelial Growth Factor and Erythropoietin through Decreasing Hypoxia Inducible Factor-1 α and Inhibits Angiogenesis.
Authors: Shigehiko Imagawa, Ken Matsumoto, Naoshi Obara, Norio Suzuki, Toshiro Nagasawa, Masayuki Yamamoto
Journal: Blood (2005)
EVI-1 Mediates Apoptosis Resistance Via CD261 Induction and Enhances Leukemogenic Potential in Human Acute Lymphoblastic Leukemia
Authors: Martina Konantz, Maya Caroline Andre, Martin Ebinger, Matthias Grauer, Hui Wang, Sarah Grzywna, Helmut R. Salih, Rupert Handgretinger, Olga S. Kustikova, Christopher Baum, Lothar Kanz, Klaus Schulze-Osthoff, Leticia Quintanilla-Martinez, Frank Essmann, Claudia Lengerke
Journal: Blood (2011)
Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study
Authors: Jingjing Quan, Xi Li, Yan Chen, Yan Jiang, Zhihui Zhou, Huichuan Zhang, Lu Sun, Zhi Ruan, Ye Feng, Murat Akova, Yunsong Yu
Journal: The Lancet Infectious Diseases (2017)
ERCC1, KRAS mutation, and oxaliplatin sensitivity in colorectal cancer: Old dogs and new tricks.
Authors: Armando Orlandi, Mariantonietta Di Salvatore, Michele Basso, Cinzia Bagalà, Antonia Strippoli, Francesca Plastino, Enzo Dadduzio, Simona Di Lascio, Michela Quirino, Alessandra Cassano, Antonio Astone, Carlo Barone
Journal: Journal of Clinical Oncology (2012)

489 Background: Oxaliplatin is widely used in metastatic colorectal cancer, but currently there are not valid predictors of response to this drug. In our recent retrospective clinical study we have shown a greater efficacy of Oxaliplatin in patients with metastatic colorectal cancer with mutated (mt) K-RAS. We hypothesized that the mutational status of K-RAS could influence the expression of ERCC1, one of the main mechanisms of Oxaliplatin resistance. Methods: We used four cell lines of colorectal cancer: two K-RAS wild type (wt) (HCT-8 and HT-29) and two K-RAS mt (SW620 and SW480). We evaluated the sensitivity of these cell lines to Oxaliplatin by MTT-test and the ERCC1 levels before and after 24 h exposure to Oxaliplatin by Real-Time PCR. We silenced K-RAS in a K-RAS mt cell line to evaluate the impact on Oxaliplatin sensitivity and ERCC1 levels. We also silenced ERCC1 in order to confirm the importance of this protein as a Oxaliplatin resistance factor. Results: The K-RAS mt cell lines were more sensitive to Oxaliplatin (OR 2.68; IC 95% 1.511-4.757 p&lt;0.001). The basal levels of ERCC1 did not show significant differences between K-RAS mt and wt cell line, however, after 24 h exposure to Oxaliplatin, only the K-RAS wt lines showed the ability to induce ERCC1, with a statistically significant difference (OR 42.9 IC 95% 17.260-106.972 p&lt;0.0005). The silencing of K-RAS in K-RAS mt cell lines demonstrated to reduce sensitivity to Oxaliplatin associated with the acquisition of the ability to induce ERCC1. The silencing of ERCC1 in K-RAS wt cell lines enhance the sensibility to Oxaliplatin. Conclusions: The K-RAS mutated cell lines were more sensitive to Oxaliplatin. This feature seems to be secondary to the inability of these cells to induce ERCC1 after exposure to Oxaliplatin. K-RAS can thus be a predictor of response to Oxaliplatin in colorectal cancer representing a surrogate for ability to induce ERCC1.
A multimarker multi‐time point‐based risk stratification strategy in acute heart failure: results from the <scp>RELAX‐AHF</scp> trial
Authors: Biniyam G. Demissei, Gad Cotter, Margaret F. Prescott, G. Michael Felker, Gerasimos Filippatos, Barry H. Greenberg, Peter S. Pang, Piotr Ponikowski, Thomas M. Severin, Yi Wang, Min Qian, John R. Teerlink, Marco Metra, Beth A. Davison, Adriaan A. Voors
Journal: European Journal of Heart Failure (2017)
Simultaneous Loss of Mouse Dematin and beta-Adducin Results in Severe Erythrocyte Fragility and Hemolytic Anemia.
Authors: Anwar A. Khan, Huiqing Chen, Diana M. Gilligan, Luanne L. Peters, Joanne Messick, Wanda M. Haschek-Hock, Fei Liu, Agnes E. Ostafin, Athar H. Chishti
Journal: Blood (2005)
Ongoing outbreak of invasive and non-invasive disease due to group A Streptococcus (GAS) type emm66 among homeless and people who inject drugs in England and Wales, January to December 2016
Authors: Nick Bundle, Laura Bubba, Juliana Coelho, Rachel Kwiatkowska, Rachel Cloke, Sarah King, Jill Rajan-Iyer, Max Courtney-Pillinger, Charles R Beck, Vivian Hope, Theresa Lamagni, Colin S Brown, Daiga Jermacane, Rachel Glass, Monica Desai, Maya Gobin, Sooria Balasegaram, Charlotte Anderson
Journal: Eurosurveillance (2017)

We report an outbreak of invasive and non-invasive disease due to an unusual type of Streptococcus pyogenes (group A Streptococcus, emm66) among a vulnerable, largely homeless population in southern England and Wales, detected in September 2016. Twenty-seven confirmed cases were subsequently identified between 5 January and 29 December 2016; 20 injected drugs and six reported problematic alcohol use. To date, we have ruled out drug-related vehicles of infection and identified few common risk factors.
Hunt wants “new relationship” with Europe on health after Brexit
Authors: Adrian O’Dowd
Journal: BMJ (2017)

The UK will seek to maintain a “positive relationship” with Europe on issues that affect health and the NHS, despite the Brexit vote to leave the European Union, England’s health secretary, Jeremy Hunt, has told MPs.

Appearing before the House of Commons Health Committee on 24 January at an evidence session for its inquiry into Brexit’s effect on health and social care, Hunt said that he did not see the impending departure as a “divorce” but the start of a “new relationship.”

“The Brexit change does not mean that we are going to replace one set of rules with a completely new set of rules,” he said. “It …
N-Methyl-2-Pyrrolidone Is a Biologically Active Thalidomide Subunit with In Vivo anti-Myeloma Properties
Authors: Jake Shortt, Andy Hsu, Geoffrey M Matthews, Marta Chesi, P.Leif Bergsagel, Grant A. McArthur, Paul Neeson, David Ritchie, Ricky W Johnstone
Journal: Blood (2010)
Controlling the Misuse of CPR Through POLST and Certified Patient Decision Aids
Authors: Thaddeus Mason Pope
Journal: The American Journal of Bioethics (2017)

Rosoff and Schneiderman have issued a compelling warning about the “fetishization” of cardiopulmonary resuscitation (CPR) (Rosoff and Schneiderman 2017). I agree with their core thesis. We should h...